GlaxoSmithKline PLC Financials

GSK Stock  USD 42.99  0.20  0.47%   
Based on the measurements of operating efficiency obtained from GlaxoSmithKline PLC's historical financial statements, GlaxoSmithKline PLC ADR is doing better financially then in previous quarter. It has a moderate probability of reporting better financial numbers in April. At this time, GlaxoSmithKline PLC's Common Stock Shares Outstanding is quite stable compared to the past year. Short Term Investments is expected to rise to about 2.4 B this year, although the value of Total Current Liabilities will most likely fall to about 11.2 B. Key indicators impacting GlaxoSmithKline PLC's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Net Profit Margin0.220.1625
Significantly Up
Pretty Stable
Return On Assets0.150.0835
Way Up
Slightly volatile
Operating IncomeBB
Way Down
Pretty Stable
Current Ratio1.510.8849
Way Up
Slightly volatile
The financial analysis of GlaxoSmithKline PLC is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for GlaxoSmithKline PLC includes many different criteria found on its balance sheet. For example, investors should never minimize GlaxoSmithKline PLC's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor GlaxoSmithKline PLC's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in GlaxoSmithKline PLC.

Net Income

3.42 Billion

With this module, you can analyze GlaxoSmithKline financials for your investing period. You should be able to track the changes in GlaxoSmithKline PLC individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past GlaxoSmithKline PLC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of GlaxoSmithKline PLC's financial statements are interrelated, with each one affecting the others. For example, an increase in GlaxoSmithKline PLC's assets may result in an increase in income on the income statement.
Evaluating GlaxoSmithKline PLC's financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of GlaxoSmithKline PLC's profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the GlaxoSmithKline PLC's relative financial performance

Chance Of Distress

Less than 10

 
100  
 
Zero
Low
GlaxoSmithKline PLC ADR has less than 10 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for GlaxoSmithKline PLC stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, GlaxoSmithKline PLC's odds of distress score SHOULD NOT be confused with the real chance of GlaxoSmithKline PLC ADR filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as GlaxoSmithKline is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include GlaxoSmithKline PLC's liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in GlaxoSmithKline PLC's official financial statements usually reflect GlaxoSmithKline PLC's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of GlaxoSmithKline PLC ADR. For example, before you start analyzing numbers published by GlaxoSmithKline accountants, it's critical to develop an understanding of what GlaxoSmithKline PLC's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of GlaxoSmithKline PLC's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, GlaxoSmithKline PLC's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in GlaxoSmithKline PLC's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of GlaxoSmithKline PLC ADR. Please utilize our Beneish M Score to check the likelihood of GlaxoSmithKline PLC's management manipulating its earnings.

GlaxoSmithKline PLC Company Summary

GlaxoSmithKline PLC competes with Agilent Technologies, Mustang Bio, Moleculin Biotech, Seres Therapeutics, and Madrigal Pharmaceuticals. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Gsk Plc is traded on New York Stock Exchange in the United States.
Foreign Associate
  UK
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNew York Stock Exchange
ISINUS37733W2044
CUSIP37733W105 37733W204
LocationUnited Kingdom
Business Address980 Great West
SectorPharmaceuticals
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.gsk.com
Phone44 20 8047 5000
CurrencyUSD - US Dollar
You should never invest in GlaxoSmithKline PLC without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of GlaxoSmithKline Stock, because this is throwing your money away. Analyzing the key information contained in GlaxoSmithKline PLC's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

GlaxoSmithKline PLC Key Financial Ratios

Generally speaking, GlaxoSmithKline PLC's financial ratios allow both analysts and investors to convert raw data from GlaxoSmithKline PLC's financial statements into concise, actionable information that can be used to evaluate the performance of GlaxoSmithKline PLC over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that GlaxoSmithKline PLC ADR reports annually and quarterly.

GlaxoSmithKline PLC Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets79.7B80.4B79.1B60.1B59.0B32.8B
Other Current Liab755M765M958M2.3B14.3B15.0B
Net Debt25.8B20.9B19.9B17.3B15.1B8.3B
Accounts Payable14.9B15.8B17.6B16.3B3.7B6.2B
Cash4.7B6.3B4.3B3.7B2.9B2.7B
Inventory5.9B6.0B5.8B5.1B5.5B3.0B
Total Liab61.3B59.6B57.8B50.1B46.2B25.5B
Total Current Assets19.5B20.2B18.7B20.8B18.6B11.9B
Short Term Debt6.9B3.7B3.6B4.0B2.8B2.2B
Common Stock1.3B1.3B1.3B1.3B1.3B1.3B
Retained Earnings5.1B6.8B7.9B4.4B7.2B7.6B
Intangible Assets31.0B29.8B30.1B14.3B14.8B11.4B
Other Liab13.7B14.1B13.5B10.2B11.7B14.2B
Long Term Debt22.6B23.4B20.6B17.0B14.2B17.5B
Good Will10.6B10.6B10.6B7.0B6.8B5.3B
Other Current Assets1.6B617M525M7.7B561M533.0M
Other Assets5.1B5.3B6.9B6.9B7.9B5.4B
Net Receivables7.1B7.3B8.0B7.1B7.4B6.5B
Net Tangible Assets(30.1B)(25.8B)(25.6B)(10.8B)(12.4B)(13.0B)
Short Long Term Debt6.7B3.5B3.4B3.8B2.7B4.3B
Long Term Debt Total23.6B23.4B20.6B17.0B19.6B20.5B

GlaxoSmithKline PLC Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what GlaxoSmithKline PLC's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Interest Expense912M892M784M879M775M502.2M
Total Revenue33.8B34.1B34.1B29.3B30.3B19.9B
Gross Profit21.9B22.4B22.5B19.8B21.3B14.6B
Operating Income7.0B7.8B6.2B6.4B7.0B5.0B
Ebit7.0B7.8B6.2B6.4B7.0B5.2B
Research Development4.6B5.1B5.3B5.5B5.2B3.0B
Ebitda10.1B8.5B8.8B8.8B9.3B6.4B
Income Before Tax6.2B7.0B5.4B5.6B6.1B4.8B
Net Income4.6B5.7B4.4B4.9B4.9B3.4B
Income Tax Expense953M580M346M707M756M1.2B
Cost Of Revenue11.9B11.7B11.6B9.6B9.1B7.7B
Minority Interest7.0B6.2B(711M)(665M)(380M)(361M)
Tax Provision953M580M346M707M756M669.3M
Interest Income708M44M723M76M48M45.6M
Net Interest Income(840M)(848M)(756M)(803M)(735M)(771.8M)

GlaxoSmithKline PLC Key Cash Accounts

Cash flow analysis captures how much money flows into and out of GlaxoSmithKline PLC ADR. It measures of how well GlaxoSmithKline is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money GlaxoSmithKline PLC brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money GlaxoSmithKline had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what GlaxoSmithKline PLC has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201920202021202220232024 (projected)
Change To Inventory300M119M25M(269M)(424M)(402.8M)
Change In Cash744M431M(1.4B)(394M)(787M)(747.7M)
Free Cash Flow5.9B6.2B5.0B5.1B4.0B3.4B
Depreciation3.0B624M2.5B2.3B2.3B1.4B
Other Non Cash Items814M848M756M(433M)540M567M
Capital Expenditures2.2B2.2B2.9B2.3B2.3B1.5B
Net Income5.3B6.4B5.1B4.9B4.9B4.6B
End Period Cash Flow4.8B5.3B3.8B3.4B2.9B2.1B
Dividends Paid4.0B4.0B4.0B3.5B(2.2B)(2.1B)
Investments(5.4B)2.2B334M(8.8B)(1.6B)(1.5B)
Net Borrowings3.5B(4.2B)(2.2B)(4.8B)(5.5B)(5.8B)
Change To Netincome670M380M105M(8.3B)(9.6B)(10.1B)

GlaxoSmithKline Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining GlaxoSmithKline PLC's current stock value. Our valuation model uses many indicators to compare GlaxoSmithKline PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GlaxoSmithKline PLC competition to find correlations between indicators driving GlaxoSmithKline PLC's intrinsic value. More Info.
GlaxoSmithKline PLC ADR is one of the top stocks in return on asset category among related companies. It is rated below average in current ratio category among related companies fabricating about  16.23  of Current Ratio per Return On Asset. At this time, GlaxoSmithKline PLC's Current Ratio is quite stable compared to the past year.. Comparative valuation analysis is a catch-all model that can be used if you cannot value GlaxoSmithKline PLC by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for GlaxoSmithKline PLC's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the GlaxoSmithKline PLC's earnings, one of the primary drivers of an investment's value.

GlaxoSmithKline PLC ADR Systematic Risk

GlaxoSmithKline PLC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. GlaxoSmithKline PLC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on GlaxoSmithKline PLC ADR correlated with the market. If Beta is less than 0 GlaxoSmithKline PLC generally moves in the opposite direction as compared to the market. If GlaxoSmithKline PLC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one GlaxoSmithKline PLC ADR is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of GlaxoSmithKline PLC is generally in the same direction as the market. If Beta > 1 GlaxoSmithKline PLC moves generally in the same direction as, but more than the movement of the benchmark.

About GlaxoSmithKline PLC Financials

What exactly are GlaxoSmithKline PLC Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include GlaxoSmithKline PLC's income statement, its balance sheet, and the statement of cash flows. Potential GlaxoSmithKline PLC investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although GlaxoSmithKline PLC investors may use each financial statement separately, they are all related. The changes in GlaxoSmithKline PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GlaxoSmithKline PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze GlaxoSmithKline PLC Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as GlaxoSmithKline PLC is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of GlaxoSmithKline has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if GlaxoSmithKline PLC's financials are consistent with your investment objective using the following steps:
  • Review GlaxoSmithKline PLC's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand GlaxoSmithKline PLC's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare GlaxoSmithKline PLC's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if GlaxoSmithKline PLC's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

GlaxoSmithKline PLC Thematic Clasifications

GlaxoSmithKline PLC ADR is part of Healthcare investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
HealthcareView
This theme covers USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in GlaxoSmithKline PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various GlaxoSmithKline PLC's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of GlaxoSmithKline PLC growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.5)

At this time, GlaxoSmithKline PLC's Price Earnings To Growth Ratio is quite stable compared to the past year.

GlaxoSmithKline PLC March 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of GlaxoSmithKline PLC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of GlaxoSmithKline PLC ADR. We use our internally-developed statistical techniques to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on widely used predictive technical indicators. In general, we focus on analyzing GlaxoSmithKline Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build GlaxoSmithKline PLC's daily price indicators and compare them against related drivers.
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Complementary Tools for GlaxoSmithKline Stock analysis

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Dividend Share
0.58
Earnings Share
3.02
Revenue Per Share
14.97
Quarterly Revenue Growth
0.092
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.